Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL9 | O00512 | 1/20 | 0.56 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.56 |
| ▸ | HTR2A | P28223 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MGLL | Q99685 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.42 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.42 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29189078 | 0.93 | BCL9 (0.59) | BCL9CTNNB1HTR2AGAAMAPT | |
| SCHEMBL6444724 | 0.89 | BCL9 (0.59) | BCL9CTNNB1HTR2AGAAMAPT | |
| SCHEMBL29189081 | 0.88 | BCL9 (0.54) | BCL9CTNNB1HTR2AGAAMAPT | |
| SCHEMBL6577540 | 0.88 | BCL9 (0.74) | BCL9CTNNB1HTR2AGAAMAPT | |
| SCHEMBL3468592 | 0.86 | HTR2A (0.56) | BCL9CTNNB1HTR2AGAAMAPT | |
| SCHEMBL27557226 | 0.86 | BCL9 (0.74) | BCL9CTNNB1HTR2AGAAMAPT | |
| SCHEMBL5762656 | 0.85 | BCL9 (0.60) | BCL9CTNNB1HTR2AGAAMAPT | |
| SCHEMBL30967403 | 0.85 | HTR2A (0.55) | BCL9CTNNB1HTR2AGAAMAPT | |
| SCHEMBL6395955 | 0.84 | BCL9 (0.60) | BCL9CTNNB1HTR2AGAAMAPT | |
| SCHEMBL31331481 | 0.83 | BCL9 (0.59) | BCL9CTNNB1HTR2AGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2928902-B1 | CONJUGATE COMPOUNDS | VICTORIA LINK LTD (NZ) | 2019-07-17 | — | — | EP | disclosed |
| EP-2928902-B1 | CONJUGATE COMPOUNDS | VICTORIA LINK LTD (NZ) | 2019-07-17 | — | — | EP | disclosed |
| US-9764037-B2 | Conjugate compounds | VICTORIA LINK LIMITED (NZ) | 2017-09-19 | — | — | US | disclosed |
| US-9764037-B2 | Conjugate compounds | VICTORIA LINK LIMITED (NZ) | 2017-09-19 | — | — | US | disclosed |
| US-9764037-B2 | Conjugate compounds | VICTORIA LINK LIMITED (NZ) | 2017-09-19 | — | — | US | disclosed |
| US-20170119875-A1 | AMINO SPHINGOGLYCOLIPID ANALOGUES | VICTORIA LINK LIMITED (NZ) | 2017-05-04 | — | — | US | disclosed |
| US-20170119875-A1 | AMINO SPHINGOGLYCOLIPID ANALOGUES | VICTORIA LINK LIMITED (NZ) | 2017-05-04 | — | — | US | disclosed |
| US-20170119875-A1 | AMINO SPHINGOGLYCOLIPID ANALOGUES | VICTORIA LINK LIMITED (NZ) | 2017-05-04 | — | — | US | disclosed |
| US-9586985-B2 | Organic compounds as proantigens for natural killer T cells | VICTORIA LINK LIMITED (NZ) | 2017-03-07 | — | — | US | disclosed |
| US-9586985-B2 | Organic compounds as proantigens for natural killer T cells | VICTORIA LINK LIMITED (NZ) | 2017-03-07 | — | — | US | disclosed |
| US-20150352219-A1 | CONJUGATE COMPOUNDS | VICTORIA LINK LIMITED (NZ) | 2015-12-10 | — | — | US | disclosed |
| EP-2928902-A1 | CONJUGATE COMPOUNDS | Callaghan Innovation Research Limited (NZ) | 2015-10-14 | — | — | EP | disclosed |
| US-20150191503-A1 | ORGANIC COMPOUNDS | VICTORIA LINK LIMITED (NZ) | 2015-07-09 | — | — | US | disclosed |
| US-20150191503-A1 | ORGANIC COMPOUNDS | VICTORIA LINK LIMITED (NZ) | 2015-07-09 | — | — | US | disclosed |
| US-20150191503-A1 | ORGANIC COMPOUNDS | VICTORIA LINK LIMITED (NZ) | 2015-07-09 | — | — | US | disclosed |
| EP-2877481-A1 | ORGANIC COMPOUNDS | Callaghan Innovation Research Limited (NZ) | 2015-06-03 | — | — | EP | disclosed |
| WO-2014088432-A1 | CONJUGATE COMPOUNDS | CALLAGHAN INNOVATION RESEARCH LIMITED (NZ) | 2014-06-12 | — | — | WO | disclosed |
| WO-2014088432-A1 | CONJUGATE COMPOUNDS | CALLAGHAN INNOVATION RESEARCH LIMITED (NZ) | 2014-06-12 | — | — | WO | disclosed |
| WO-2014017928-A1 | ORGANIC COMPOUNDS | CALLAGHAN INNOVATION RESEARCH LIMITED (NZ) | 2014-01-30 | — | — | WO | disclosed |
| WO-2014017928-A1 | ORGANIC COMPOUNDS | CALLAGHAN INNOVATION RESEARCH LIMITED (NZ) | 2014-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170119875-A1 | AMINO SPHINGOGLYCOLIPID ANALOGUES | SGMS1, ENPP2, SGMS2 | BCL9 628/4885CTNNB1 4730/4885HTR2A 3626/4885 |
| US-20150191503-A1 | ORGANIC COMPOUNDS | SGMS1, UGCG, SGMS2 | BCL9 557/4885CTNNB1 3547/4885HTR2A 4449/4885 |
| US-20150352219-A1 | CONJUGATE COMPOUNDS | SGMS1, SGMS2, ENPP2 | BCL9 606/4885CTNNB1 4858/4885HTR2A 4549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.